for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Spectrum Pharmaceuticals, Inc.

SPPI.OQ

Latest Trade

8.95USD

Change

-0.50(-5.29%)

Volume

1,630,262

Today's Range

8.84

 - 

9.55

52 Week Range

6.23

 - 

21.80

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
9.45
Open
9.55
Volume
1,630,262
3M AVG Volume
16.66
Today's High
9.55
Today's Low
8.84
52 Week High
21.80
52 Week Low
6.23
Shares Out (MIL)
112.86
Market Cap (MIL)
1,010.06
Forward P/E
-7.80
Dividend (Yield %)
--

Next Event

Spectrum Pharmaceuticals Inc at Cantor Fitzgerald Global Healthcare Conference

Latest Developments

More

Spectrum Pharmaceuticals Reports Q2 Loss Per Share $0.26

Spectrum Announces Expansion Of Poziotinib Clinical Program

Spectrum Pharmaceuticals Announces Integrated Results From Two Phase 3 Rolontis® Trials

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company operates through developing and commercializing oncology and hematology drug products segment. It focuses on developing ROLONTIS and POZIOTINIB. ROLONTIS is being investigated for the treatment of chemotherapy-induced neutropenia. POZIOTINIB is an oral pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR, HER) Family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.

Industry

Biotechnology & Drugs

Contact Info

11500 S Eastern Ave Ste 240

+1.702.8356300

https://www.sppirx.com/

Executive Leadership

William L. Ashton

Chairman of the Board

Joseph W. Turgeon

President, Chief Executive Officer, Director

Kurt A. Gustafson

Chief Financial Officer, Executive Vice President

Thomas J. Riga

Chief Operating Officer, Chief Commercial Officer, Executive Vice President

Keith M. McGahan

Senior Vice President, Chief Legal Officer and Corporate Secretary

Key Stats

1.60 mean rating - 5 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.1K

2017

0.1K

2018

0.1K

2019(E)

0.0K
EPS (USD)

2016

-0.940

2017

-1.070

2018

-0.840

2019(E)

-1.148
Price To Earnings (TTM)
--
Price To Sales (TTM)
18.48
Price To Book (MRQ)
3.96
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-58.68
Return on Equity (TTM)
-47.39

Latest News

BRIEF-Spectrum Pharmaceuticals Reports Q1 Non-GAAP Loss Per Share $0.15

* SPECTRUM PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PIPELINE UPDATE

BRIEF-Spectrum Pharmaceuticals Enters Into A Next-Generation Sequencing Companion Diagnostic Partnership With Thermo Fisher Scientific

* SPECTRUM PHARMACEUTICALS ENTERS INTO A NEXT-GENERATION SEQUENCING COMPANION DIAGNOSTIC PARTNERSHIP WITH THERMO FISHER SCIENTIFIC

BRIEF-Shrotriya May Sell Up To 1 Mln Shares Of Spectrum Pharmaceuticals' Common Stock

* RAJESH C. SHROTRIYA - SHROTRIYA MAY SELL UP TO 1 MILLION SHARES OF SPECTRUM PHARMACEUTICALS' COMMON STOCK BETWEEN MARCH 26 AND JUNE 29 - SEC FILING Source text: (https://bit.ly/2pKokJc) Further company coverage:

BRIEF-Spectrum Pharma Q4 Loss Per Share $0.29

* SPECTRUM PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 AND FULL YEAR 2017 FINANCIAL RESULTS AND PIPELINE UPDATE

BRIEF-Spectrum Pharmaceuticals Announces Appointment Of William Ashton To Its Board

* SPECTRUM PHARMACEUTICALS ANNOUNCES APPOINTMENT OF WILLIAM L. ASHTON TO ITS BOARD OF DIRECTORS

BRIEF-Spectrum Pharmaceuticals Announces Rolontis Met The Primary Endpoint In The Phase 3 Advance Study

* SPECTRUM PHARMACEUTICALS ANNOUNCES ROLONTIS™ (EFLAPEGRASTIM) MET THE PRIMARY ENDPOINT IN THE PHASE 3 ADVANCE STUDY

BRIEF-Spectrum Pharmaceuticals Says Expect To File A Registration Application (Bla) With FDA For Rolontis

* SPECTRUM PHARMACEUTICALS SAYS EXPECT TO FILE A REGISTRATION APPLICATION (BLA) WITH FDA FOR ROLONTIS IN Q4 2018 - SEC FILING Source text for Eikon: (http://bit.ly/2EmWf09) Further company coverage:

BRIEF-Spectrum Pharmaceuticals reports Q3 non-GAAP loss per share of $0.11

* Spectrum Pharmaceuticals reports third quarter 2017 financial results and pipeline update

BRIEF-Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer patients with Exon 20 insertion mutation in EGFR or HER2

* Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC) patients with Exon 20 insertion mutation in EGFR or HER2 Source text for Eikon: Further company coverage:

BRIEF-Spectrum Pharma to exchange $69.5 million in principal amount of its 2.75% convertible senior notes due 2018 for common stock and cash

* Spectrum Pharmaceuticals announces agreements to exchange $69.5 million in principal amount of its 2.75% convertible senior notes due 2018 for common stock and cash

BRIEF-Spectrum Pharmaceuticals provides update on at-the-market facility

* Spectrum Pharmaceuticals Inc provides update on at-the-market facility

BRIEF-Spectrum Pharma starts phase 3 qapzola trial

* Spectrum pharmaceuticals announces initiation of the registrational phase 3 trial of qapzola™ (apaziquone) in patients with non-muscle invasive bladder cancer (nmibc)

BRIEF-Spectrum Pharma enters into an at market issuance sales agreement

* Spectrum Pharmaceuticals Inc - on August 4, 2017, co entered into an at market issuance sales agreement - sec filing

BRIEF-Spectrum Pharmaceuticals Q2 loss per share $0.26

* Spectrum Pharmaceuticals reports second quarter 2017 financial results and pipeline update

BRIEF-Spectrum Pharmaceuticals announces ‍enrollment in Rolontis phase 3 advance pivotal study​

* Spectrum Pharmaceuticals Inc - enrollment with 405 patients randomized in rolontis phase 3 advance pivotal study

BRIEF-Spectrum Pharmaceuticals says stockholders did not approve by advisory vote executive compensation at annual meeting

* Spectrum Pharmaceuticals Inc - stockholders did not approve by advisory vote executive compensation at annual meeting Source text: (http://bit.ly/2sHq6yo) Further company coverage:

BRIEF-Spectrum Pharmaceuticals reports Q1 loss per share $0.29

* Spectrum Pharmaceuticals reports first quarter 2017 financial results and pipeline update

BRIEF-Spectrum Pharmaceuticals announces initiation of a phase 2 trial of Poziotinib

* Spectrum Pharmaceuticals announces initiation of a phase 2 trial of Poziotinib in non-small cell lung cancer patients with EGFR exon 20 insertion mutations

BRIEF-Spectrum Pharmaceuticals reports Q4 loss per share of $0.22

* Spectrum Pharmaceuticals reports fourth quarter 2016 and full year 2016 financial results and pipeline update

Spectrum Pharma says FDA rejects its bladder cancer drug

Spectrum Pharmaceuticals Inc said on Friday the U.S. Food and Drug Administration had rejected the drugmaker's bladder cancer treatment, apaziquone.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up